O'Donnell J, Trokoudes K, Silverberg J, Row V, Volpé R
J Clin Endocrinol Metab. 1978 May;46(5):770-7. doi: 10.1210/jcem-46-5-770.
A radioreceptor assay for human thyroid stimulators has been employed in various groups of patients. The ability of Ig to displace the labeled TSH from the receptors is referred to as "TSH displacement activity (TDA)." In active Graves' disease, TDA was above normal in 76% of the cases, and in the remaining patients, it was above the 76th percentile, suggesting that thyroid-stimulating Ig (TSIg) may have been present in all cases, but not always demonstrable by this method. Significant TDA was not found in normal persons or in toxic or nontoxic nodular goiters. It was also negative in some patients with "euthyroid ophthalmic Graves' disease." In patients with Graves' disease controlled with antithyroid drugs, positive TDA accurately predicted the recurrence of hyperthyroidism in eight of nine cases from whom the drugs were withdrawn. Thus, TSIg appears to be a prerequisite of the hyperthyroidism of Graves' disease. Moreover, the remission of hyperthyroidism was due to the disappearance of TSIg (immunological remission) in most cases in this small series. Serum TDA may provide a means of detecting immunological remission. The exophthalmos of Graves' disease does not require thyroid-stimulating Ig.
一种用于检测人甲状腺刺激物的放射受体测定法已应用于各类患者群体。免疫球蛋白(Ig)从受体上置换标记促甲状腺激素(TSH)的能力被称为“TSH置换活性(TDA)”。在活动性格雷夫斯病中,76%的病例TDA高于正常水平,其余患者则高于第76百分位数,这表明所有病例中可能都存在甲状腺刺激免疫球蛋白(TSIg),但并非总能通过这种方法检测到。正常人和毒性或非毒性结节性甲状腺肿患者未发现显著的TDA。一些“甲状腺功能正常的格雷夫斯眼病”患者的TDA也呈阴性。在用抗甲状腺药物控制的格雷夫斯病患者中,阳性TDA准确预测了9例停药患者中有8例甲状腺功能亢进症复发。因此,TSIg似乎是格雷夫斯病甲状腺功能亢进症的一个先决条件。此外,在这个小系列的大多数病例中,甲状腺功能亢进症的缓解是由于TSIg消失(免疫缓解)。血清TDA可能提供一种检测免疫缓解的方法。格雷夫斯病的突眼不需要甲状腺刺激免疫球蛋白。